Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Paracetamol for Catheter Related Bladder Discomfort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01652183
Recruitment Status : Completed
First Posted : July 27, 2012
Last Update Posted : July 27, 2012
Information provided by (Responsible Party):
Pinar Ergenoglu, Baskent University

Brief Summary:
The insertion of an urinary catheter in a patient undergoing a surgical procedure, especially in urinary interventions, may lead to catheter-related bladder discomfort with varying degrees of severity during the postoperative period. Catheter-related bladder discomfort (CRBD) symptoms associated with indwelling urinary catheter are similar to overactive bladder symptoms such as discomfort in the suprapubic region, urinary urgency, frequency, burning sensation with or without urge incontinence. Paracetamol is a drug with proven efficiency for the management of mild and moderate postoperative pain. In this study, the investigators hypothesized to address the effect of single-dose intravenous paracetamol on postoperative CRBD following percutaneous nephrolithotomy surgery (PNL).

Condition or disease Intervention/treatment Phase
Catheter Related Bladder Discomfort Drug: intravenous paracetamol Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : October 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : November 2009

Arm Intervention/treatment
Placebo Comparator: Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl Drug: Placebo
Active Comparator: Group Paracetamol(n=32):iv 15mg/kg paracetamol
The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
Drug: intravenous paracetamol
Other Name: 30.11.2005-118/79

Primary Outcome Measures :
  1. Reducing of Catheter related bladder discomfort symptoms [ Time Frame: CRBD was evaluated at postoperatively 30th minutes, 1st, 2nd, 4th, 6th and 12th hours ]
    CRBD was evaluated with a 4 point scale (1; no discomfort, 2; mild, revealed on questioning only, 3; moderate, stated by the patient without questioning, 4; severe, urinary urgency executed by behavioral responses, such as attempts to remove urinary catheter, restless extremity movements, verbal responses) at postoperatively 30th minutes, 1st, 2nd, 4th, 6th and 12th hours.

Secondary Outcome Measures :
  1. Assessment of CRBD symptoms by the evaluation of VAS, sedation scales and hemodynamic findings [ Time Frame: at postoperatively 30th minutes, 1st, 2nd, 4th, 6th and 12th hours. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 years of age,
  • American Society of Anesthesiologists (ASA) Physical Status of I-II,
  • undergoing PNL with urinary bladder catheter.

Exclusion Criteria:

  • obesity (BMI > 30),
  • chronic opioid use,
  • bladder outflow obstruction,
  • benign prostatic hyperplasia, and
  • overactive bladder (OAB) (frequency > 3 times at night or > 8 times within 24h).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01652183

Layout table for location information
Baskent University School of Medicine Adana Teaching and Research Hospital
Adana, Turkey, 01250
Sponsors and Collaborators
Pinar Ergenoglu

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pinar Ergenoglu, Baskent University School of Medicine Adana Teaching and Research Hospital, Baskent University Identifier: NCT01652183    
Other Study ID Numbers: KA08/180
First Posted: July 27, 2012    Key Record Dates
Last Update Posted: July 27, 2012
Last Verified: July 2012
Keywords provided by Pinar Ergenoglu, Baskent University:
Intravenous paracetamol
catheter related bladder discomfort
urologic surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs